Table 5 Clinical application of cytokines T cell lymphoma
From: Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
Lymphoma subtypes | Author | PMID/doi | Biomarker | Liquid Biopsy | Method | No. of patients | Results | Clinical applications |
|---|---|---|---|---|---|---|---|---|
ENKTL | Heemann, Christina et al. [144] | 22573350 | cytokines, sTNFRII | PB | ELISA, sTNFRI, sTNFRII, IL-10, and sIL-4R | 117 | sTNFRII serum levels ≥ 2.16 ng/mL had a 2.07-fold increased relative risk for shorter overall survival (OS; univariate: P = 0.0034; multivariate: HR, 2.07; CI, 0.92–4.70 with P = 0.081) and a 2.49-fold higher risk for shorter EFS (univariate: P = 0.00068; multivariate: HR, 2.49; CI, 1.22–5.08 with P = 0.012) | prognosis |
ENKTL | Ni, Mingli et al. [181] | 30643796 | cytokine, IL-13 | PB | ELISA | 15 | IL-13 inhibited chemotherapy sensitivity of NK/T-cell lymphoma cells by promoting ABCC4 expression | drug resistance |
ENKTL | Huo, Jia et al. [182] | 35226228 | cytokine, IL-10 | PB | ELISA | 50 | IL-10 contributes to the resistance of ENKTL cells by promoting ABCC4 expression | drug resistance |